Shortwave Life Sciences PLC – London-based drug development for mental health – Changes name from Psych Capital following the acquisition of Shortwave Pharma Inc last year. Says the new name reflects its focus on mental health, particularly eating disorders. This includes psychedelics-based therapies.

“Eating disorders, including anorexia nervosa, bulimia nervosa, and binge-eating disorder, represent a significant global health challenge, affecting millions of individuals worldwide and growing at an alarming rate,” the company says. “Shortwave Life Sciences is committed to leveraging cutting-edge drug design, novel delivery methods, and decades of drug development expertise to develop and support transformative therapies for these debilitating conditions.”